Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gower Publishing

- PMLiVE

J&J’s COVID-19 vaccine generates positive pre-clinical results

Experimental vaccine begins first-in-human trial this month

Covid-19 drives change in long-term conditions management

Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore how patients are being empowered to manage their conditions at home

Wilmington Healthcare

- PMLiVE

NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer

Picks up approval as a first-line treatment for advanced cancer

- PMLiVE

Gilead’s top-line slips 10% as demand for HIV/hepatitis C drugs drops

Disruption to uptake of HIV and hepatitis C drugs caused by pandemic

- PMLiVE

What’s next? How behavioural science can support pharma’s future

By Dan Coffin

Potential Benefits and Dangers of Big Data Analytics

In this episode of Impetus Digital's Fireside Chat, I sit down with Brenda McPhail from the Canadian Civil Liberties Association. We talk about a myriad of different subjects related to...

Impetus Digital

VR/AR Applications for Training and Healthcare

In the latest episode of Impetus Digital's Fireside Chat, I sit down with Mike Waldron, who is the CEO and Co-Founder of Propel VR. We discuss how virtual reality (VR)...

Impetus Digital

Changing and Sustaining Lifestyle Habits with Digital Therapeutics

In this fireside chat, Natalie Yeadon sat down with Jeffrey Ruby, Founder & CEO of Newtopia and discussed how a combination of genetic testing, personality-matched coaching, and smart technology can...

Impetus Digital

Secondary effects of COVID-19 on the healthcare system and patients

We are getting to the point where we need to start considering the long-term effects on the healthcare system when making decisions.

Impetus Digital

AstraZeneca AZ

AstraZeneca escapes pandemic impact as new drugs bolster revenues

Earnings climbed above expectations in the second quarter

- PMLiVE

Roche pays $120m upfront for UCB’s anti-tau Alzheimer’s drug

Milestone payments could reach up to $2bn

- PMLiVE

Boehringer/Lilly’s Jardiance hits the mark in pivotal heart failure trial

Drug reduced risk of death/hospitalisation in patients with and without diabetes

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links